NRG1 and non-small cell lung carcinoma: MCLA-128 has shown good efficacy in clinical trial (phase II: NCT03321981) in patients with breast cancer metastasis and in another clinical trial (phase I/II: NCT02912949) in patients with pancreatic cancer and non-small cell lung cancer(NSCLC) fused with NRG1 (31).